Free Trial

Protalix BioTherapeutics (PLX) Competitors

Protalix BioTherapeutics logo
$1.51 -0.04 (-2.58%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.52 +0.00 (+0.33%)
As of 07/25/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLX vs. TRML, RZLT, KMDA, PRTC, CGEM, RGNX, ERAS, AQST, SNDL, and CMPX

Should you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Tourmaline Bio (TRML), Rezolute (RZLT), Kamada (KMDA), PureTech Health (PRTC), Cullinan Therapeutics (CGEM), REGENXBIO (RGNX), Erasca (ERAS), Aquestive Therapeutics (AQST), SNDL (SNDL), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry.

Protalix BioTherapeutics vs. Its Competitors

Tourmaline Bio (NASDAQ:TRML) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 149.54%. Protalix BioTherapeutics has a consensus target price of $15.00, indicating a potential upside of 893.38%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Tourmaline Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tourmaline Bio
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tourmaline Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500.

91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 13.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tourmaline Bio has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Tourmaline Bio's return on equity of -26.75% beat Protalix BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tourmaline BioN/A -26.75% -26.11%
Protalix BioTherapeutics -21.03%-30.89%-11.74%

Protalix BioTherapeutics has higher revenue and earnings than Tourmaline Bio. Tourmaline Bio is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tourmaline BioN/AN/A-$73.21M-$3.21-6.16
Protalix BioTherapeutics$59.76M2.01$8.31M$0.0437.75

In the previous week, Tourmaline Bio and Tourmaline Bio both had 3 articles in the media. Tourmaline Bio's average media sentiment score of 1.03 beat Protalix BioTherapeutics' score of 0.25 indicating that Tourmaline Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tourmaline Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protalix BioTherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Tourmaline Bio beats Protalix BioTherapeutics on 8 of the 13 factors compared between the two stocks.

Get Protalix BioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLX vs. The Competition

MetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$120.21M$273.45M$5.70B$21.11B
Dividend YieldN/AN/A4.69%3.60%
P/E Ratio-11.62N/A28.1028.44
Price / Sales2.01364.38428.3558.68
Price / Cash17.8022.4436.2222.92
Price / Book3.2112.418.664.69
Net Income$8.31M-$106.40M$3.25B$995.51M
7 Day Performance4.14%5.20%4.22%1.65%
1 Month Performance4.14%24.18%10.51%4.54%
1 Year Performance31.88%10.55%34.40%9.99%

Protalix BioTherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLX
Protalix BioTherapeutics
2.9317 of 5 stars
$1.51
-2.6%
$15.00
+893.4%
+31.3%$120.21M$59.76M-11.62200
TRML
Tourmaline Bio
1.9066 of 5 stars
$18.23
-1.4%
$49.33
+170.6%
+15.5%$468.15MN/A-5.6844News Coverage
Positive News
RZLT
Rezolute
2.5508 of 5 stars
$5.38
-0.2%
$11.83
+120.0%
+34.6%$468.06MN/A-4.6840News Coverage
Analyst Revision
KMDA
Kamada
4.3342 of 5 stars
$7.80
+4.7%
$13.00
+66.7%
+30.0%$448.54M$167.24M26.90360News Coverage
Gap Up
PRTC
PureTech Health
2.7886 of 5 stars
$18.56
+0.3%
$45.00
+142.4%
-14.4%$445.93M$4.32M0.00100Positive News
Upcoming Earnings
CGEM
Cullinan Therapeutics
2.0211 of 5 stars
$7.52
-0.1%
$30.00
+298.9%
-58.9%$444.38MN/A0.0030Positive News
RGNX
REGENXBIO
4.1763 of 5 stars
$8.49
+4.0%
$31.63
+272.5%
-37.7%$425.86M$83.33M-2.73370News Coverage
Positive News
ERAS
Erasca
2.8999 of 5 stars
$1.50
flat
$4.57
+204.8%
-46.8%$424.94MN/A-2.42120
AQST
Aquestive Therapeutics
1.6988 of 5 stars
$4.23
+0.7%
$10.14
+139.8%
+20.3%$417.18M$57.56M0.00160
SNDL
SNDL
1.7051 of 5 stars
$1.58
+2.6%
$4.00
+153.2%
-28.9%$415.19M$671.81M-5.452,516News Coverage
Upcoming Earnings
CMPX
Compass Therapeutics
3.0262 of 5 stars
$3.07
+2.3%
$12.67
+312.6%
+202.9%$414.85M$850K0.0020Positive News

Related Companies and Tools


This page (NYSE:PLX) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners